Tango Therapeutics, Inc. (TNGX) vs Xenon Pharmaceuticals Inc. (XENE)
A side-by-side comparison of Tango Therapeutics, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
TNGX
Tango Therapeutics, Inc.
$21.90HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XENE
Xenon Pharmaceuticals Inc.
$36.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — TNGX vs XENE
growth of $100 · dividends reinvested · last 6yTNGX +125.6% (+14.5%/yr)XENE +232.5% (+22.2%/yr)XENE compounded faster over this window
TNGX XENE
TNGX vs XENE: by the numbers
- •TNGX is the larger company ($3.57B vs $3.54B market cap).
- •Both run net losses; TNGX's is the smaller (-229.92% vs -4612.13% net margin).
Metrics side by side
Valuation
| Metric | TNGX | XENE |
|---|---|---|
| P/S ratio | 66.26 | N/A |
| P/B ratio | 3.48 | 2.85 |
Profitability
| Metric | TNGX | XENE |
|---|---|---|
| Gross margin | 98.25% | 66.09% |
| Operating margin | -178.39% | -4974.27% |
| Net margin | -229.92% | -4612.13% |
| ROE | -12.08% | -32.94% |
| ROIC | -12.91% | -35.27% |
Growth (annualized)
| Metric | TNGX | XENE |
|---|---|---|
| Revenue CAGR (5Y) | 19.14% | N/A |
| Total return CAGR (5Y) | 10.60% | 4.61% |
Frequently asked
- How have TNGX and XENE total returns compared?
- Over the past 5 years, TNGX delivered 10.60% and XENE delivered 4.61% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Tango Therapeutics ROEXenon Pharmaceuticals ROETango Therapeutics operating marginXenon Pharmaceuticals operating marginTango Therapeutics revenue growthXenon Pharmaceuticals revenue growthTango Therapeutics free cash flowXenon Pharmaceuticals free cash flow
Tango Therapeutics & Xenon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.